• 
• 
• 

FDA News and Drug Updates

FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

March 08, 2019 – FDA Approvals, News & Updates

FDA Approves Pembrolizumab for Treatment of Advanced Melanoma

FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma

Adverse Effects

Understanding Immunotherapy Late Adverse Effects in Cancer Survivors

Meg Barbor, MPH

Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer

Adverse Events Associated with Checkpoint Inhibitors

Alice Goodman

Managing Radiation-Related Side Effects in Patients with Human Papillomavirus–Associated Oral Cancer

Alice Goodman

Reasons for Emergency Department Visits Related to Immune Checkpoint Inhibitor Treatment

Phoebe Starr

View All Adverse Effects Articles

Immunotherapy

Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer

Phoebe Starr

Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma

Wayne Kuznar

Nivolumab–Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Immune Checkpoint Inhibitors: Test Your Knowledge Level

Eileen Koutnik-Fotopoulos

View All Immunotherapy Articles

Conference Correspondent

Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?

The Importance of Compassion: Perspective From a Lifelong Patient

Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer

Addressing the Second Victim Phenomenon

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

View All Conference Correspondent Articles

Most Popular Articles

February 8, 2019 - FDA Approvals, News & Updates

Web Exclusives - FDA Approvals, News & Updates, In the News

February 1, 2019 - FDA Approvals, News & Updates

Web Exclusives - FDA Approvals, News & Updates, In the News

FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma

Web Exclusives - FDA Approvals, News & Updates, In the News

Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma

Wayne Kuznar

TOP - February 2019, Vol 12, No 1 - Immunotherapy, Renal-Cell Carcinoma

I. New Drugs

TOP - February 2019, Vol 12, No 1 - FDA Approvals, News & Updates